AMSTAR2

AMSTAR2
  • 文章类型: Journal Article
    评估关于运动干预对轻度认知障碍(MCI)患者认知功能的meta分析文献的方法学质量及其结果指标的证据确定性,并为临床医生和研究人员提供更可靠的决策数据。
    通过PubMed检索运动干预对轻度认知障碍患者认知功能影响的Meta分析文献,科克伦图书馆,Embase,Scopus,物理治疗证据数据库和WebofScience,所有这些都有每个数据库的搜索周期框架,直到2024年6月1日。采用AMSTAR2量表评价纳入研究的方法学质量。
    包括17项荟萃分析。AMSTAR2量表评估结果显示,有一项中等质量的研究(5.55%),七项低质量研究(38.88%),和10项非常低质量的研究(55.55%)。方法上的缺陷包括未能编制计划和提供登记号,文献筛选,数据提取,未详细描述的排除原因,系统评估的实施过程不佳,以及未能描述纳入研究的资金来源或相关利益冲突。
    荟萃分析文献的总体方法学质量较低,证据的确定性很低。我们鼓励开展高质量的随机试验以产生更有力的证据。随后的系统评价可以综合这些证据,为未来的研究和临床指南提供信息。
    UNASSIGNED: To assess the methodological quality of meta-analytic literature on exercise interventions for cognitive function in patients with mild cognitive impairment (MCI) and the certainty of evidence for its outcome indicators, and to provide clinicians and researchers with more reliable data for making decisions.
    UNASSIGNED: Meta-analytic literature related to the effect of exercise intervention on cognitive function in patients with mild cognitive impairment was searched through PubMed, Cochrane Library, Embase, Scopus, Physiotherapy Evidence Database and Web of Science, all with a search period frame of each database until June 1, 2024. The AMSTAR2 scale was used to evaluate the methodological quality of the included studies.
    UNASSIGNED: Seventeen meta-analyses were included. The AMSTAR2 scale evaluation results showed that there was one medium-quality studies (5.55%), seven low-quality studies (38.88%), and 10 very low-quality studies (55.55%). Methodological deficiencies included failure to prepare a plan and provide a registration number, literature screening, data extraction, reasons for exclusion not described in detail, poor implementation process for systematic evaluation, and failure to describe the source of funding for the included studies or relevant conflicts of interest.
    UNASSIGNED: The overall methodological quality of the meta-analytic literature is low, and the certainty of evidence is low. We encourage the conduction of high-quality randomized trials to generate stronger evidence. Subsequent systematic reviews can then synthesize this evidence to inform future research and clinical guidelines.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    这项研究的目的是评估臭氧疗法(OT)在治疗膝骨关节炎(KOA)的有效性和安全性,这是该疾病最常见的形式。我们使用“评估系统评价的计量工具”(AMSTAR2)工具分析了随机对照试验(RCT)的系统评价(SRs),以评估其质量。我们开发了一份包含8个SR(15个RCT/3,685名患者)的叙述性综合报告,以总结研究结果。AMSTAR2分析表明,所有评论的置信度都非常低。在三个SR中报告了与安慰剂组相比,使用OT减轻疼痛的统计学显着效果。在一个SR中,OT与其他疗法相当,而在其他五个SR中并不优越。六个SR强调了需要具有改进的方法学质量的额外随机对照试验,以确认OT对KOA的疗效。SRs发现改善关节功能的一致性效果较少。关于安全,7个SRs报告与OT相关的轻微不良事件发生率较低.最后,这篇综述强调了OT治疗KOA的有益效果和安全性,尤其是在疼痛控制方面。与其他疗法相比,RCT和SRs的方法学质量低限制了对该方法的有效性得出结论的可能性。确保充分遵守诸如系统审查和荟萃分析的首选报告项目(PRISMA)和AMSTAR2之类的指南,以提高该领域的SR质量。
    The objective of this study is to evaluate the effectiveness and safety of ozone therapy (OT) in the treatment of knee osteoarthritis (KOA), which is the most common form of the disease. We analysed systematic reviews (SRs) of randomised controlled trials (RCTs) using the \"A MeaSurement Tool to Assess systematic Reviews\" (AMSTAR2) instrument to evaluate their quality. We developed a narrative synthesis report with eight SRs (15 RCTs/3,685 patients) to summarise the findings. The AMSTAR2 analysis indicated that all reviews had critically low confidence ratings. Statistically significant effects in pain reduction using OT compared to placebo groups were reported in three SRs. OT was shown to be comparable to other therapies in one SR and not superior in the other five. Six SRs highlighted the need for additional RCTs with improved methodological quality to confirm the efficacy of OT for KOA. SRs found fewer consistent effects for improving joint function. Regarding safety, seven SRs reported a low prevalence of minor adverse events linked with OT. Finally, this umbrella review highlights the beneficial effects and safety of OT in the treatment of KOA, particularly in pain control. The low methodological quality of RCTs and SRs limits the possibility of drawing conclusions on the effectiveness of the procedure in comparison to other therapies. Ensure adequate compliance with guidelines such as Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and AMSTAR2 has the ability to improve the quality of SRs in this area.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Systematic Review
    通过进行系统评价(SRs)概述,系统地总结当前证据,并确定太极拳治疗成人2型糖尿病(T2DM)的临床有效性和安全性。
    在2023年7月30日之前,进行了包含五个电子数据库的系统搜索,以基于有关太极拳治疗T2DM的随机对照试验(RCT)确定相关系统评价(SRs)。使用AMeaSurement工具评估系统评论(AMSTAR2)和系统评论中的偏倚风险(ROBIS)工具评估所包括SR的方法学质量。系统审查概述的首选报告项目(PRIO-harms)清单用于促进本概述中更平衡的利弊报告。校正后的覆盖面积(CCA)用于计算重叠的主要研究的程度。主要结局指标为糖化血红蛋白(HbA1c)和空腹血糖(FBG)。而次要结局包括与健康相关的质量指标.等级(建议等级,评估,发展,和评估)框架用于评估结果措施的证据质量。
    本概述中总共包括17个合格的SR。一位SR报告了负面结论,而其余16人报告了不同结局的阳性结果。共有4个SR报告了不良事件,缺席或轻微。大多数SR表现出严重低质量(15/17)和高偏见风险(14/17),如AMSTAR2和ROBIS所示,分别。CCA为12.14%,表明初级研究的高度重叠。使用GRADE方法评估了有关太极拳治疗T2DM的24个结局的135个结果的证据。其中大多数被评为非常低。
    太极拳有望成为成人T2DM患者的一种潜在有效且安全的生活方式干预措施。特别是在改善HbA1c方面,FBG,BMI,和整体生活质量(QoL)。然而,由于当前SRs中观察到的方法学缺陷以及基于GRADE的SRs质量较低,因此应谨慎解释这些结果。此外,迫切需要额外的精心设计,高质量的RCT和SRs,以建立关于太极拳在未来治疗T2DM的有效性的有力和确凿的证据。
    https://www.crd.约克。AC.英国/PROSPERO/,标识符CRD42019140988。
    UNASSIGNED: To systematically summarize current evidence and determine the clinical effectiveness and safety of Tai Chi for type 2 diabetes mellitus (T2DM) in adults by conducting an overview of systematic reviews (SRs).
    UNASSIGNED: A systematic search encompassing five electronic databases was conducted until July 30, 2023, to identify relevant systematic reviews (SRs) based on randomized controlled trials (RCTs) concerning Tai Chi for T2DM. The methodological quality of the included SRs was assessed using the A MeaSurement Tool to Assess systematic Reviews (AMSTAR 2) and the Risk of Bias in Systematic Reviews (ROBIS) tool. The Preferred Reporting Items for Overview of Systematic Review (PRIO-harms) checklist was used to promote a more balanced reporting of benefits and harms in this overview. Corrected covered area (CCA) was used to calculate the degree of overlapping primary studies. Primary outcome measures were glycosylated hemoglobin (HbA1c) and fasting blood glucose (FBG), while secondary outcomes encompassed health-related quality measures. The GRADE (Grades of Recommendations, Assessment, Development, and Evaluation) framework was utilized to assess the quality of evidence for the outcome measures.
    UNASSIGNED: A total of 17 eligible SRs were included in this overview. One SR reported negative conclusions, while the remaining 16 reported positive ones on different outcomes. A total of 4 SRs reported adverse events, either absent or minor. Most of the SRs exhibited critically low quality (15/17) and a high risk of bias (14/17), as indicated by AMSTAR2 and ROBIS, respectively. The CCA was 12.14%, indicating a high degree of primary study overlapping. Evidence from 135 results for 24 outcomes concerning Tai Chi for T2DM was evaluated using the GRADE approach, most of which were rated very low.
    UNASSIGNED: Tai Chi shows promise as a potentially effective and safe lifestyle intervention for adults with T2DM, particularly in improving HbA1c, FBG, BMI, and overall quality of life (QoL). However, these results should be cautiously interpreted due to methodological flaws observed in the current SRs and the low quality of the SRs based on GRADE. Furthermore, there is a compelling need for additional well-designed, high-quality RCTs and SRs to establish robust and conclusive evidence regarding the efficacy of Tai Chi for managing T2DM in the future.
    UNASSIGNED: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD 42019140988.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究旨在评估慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)的系统评价/荟萃分析(SRs/MAs)的方法学质量,使用评估系统评价工具(AMSTAR2),并探讨潜在的影响因素。
    方法:PubMed,搜索EMBASE和Cochrane图书馆数据库以进行相关研究。AMSTAR2用于评估合格SRs/MA的方法学质量。使用卡方检验比较了SRs/MA的方法学特征之间的差异。在实验前,使用类内相关系数(ICC)来评估审阅者的一致性。多因素回归分析用于确定影响方法学质量的潜在因素。
    结果:共包括45个SRs/MA。经过AMSTAR2评估,45个SR/MA中只有两个(4.4%)是中等的,三个(6.7%)被评为低质量,其余40例(88.9%)被评为严重低质量。在AMSTAR2的16个项目中,项目3和项目10的遵守情况最差。项目4收到的“部分是”答复数量最多。单变量分析表明,不同大陆之间(P=0.027)以及预先注册的SR与未注册的SR之间的方法学质量存在显着差异(P=0.004)。然而,在多变量分析中,方法学质量与以下研究特征之间没有显着关联:出版年份,大陆,报告是否遵循系统审查的首选报告项目(PRISMA),预注册,资金支持,随机对照试验(RCT)登记,SR是否发布在Cochrane系统评论数据库(CDSR)中,以及是否进行荟萃分析。此外,基于介入SRs/MA的亚组分析显示,通过单变量和多变量分析,大陆与CP/CPPS的SRs/MA的方法学质量独立相关。
    结论:我们的研究表明,CP/CPPS的SRs/MA的方法学质量普遍较差。CP/CPPS的SRs/MA应采用AMSTAR2,以提高其方法学质量。
    This study aimed to assess the methodological quality of the systematic reviews/meta-analyses (SRs/MAs) of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) using A Measurement Tool to Assess systematic Reviews (AMSTAR2) and to explore the potential influencing factors.
    PubMed, EMBASE and Cochrane Library databases were searched for relevant studies. AMSTAR2 was used for evaluating the methodological quality of eligible SRs/MAs. Differences between methodological characteristics of SRs/MAs were compared using chi-square tests. The intra-class correlation coefficient (ICC) was used to assess reviewer agreement in the pre-experiment. Multivariate regression analysis was used to identify potential factors affecting methodological quality.
    A total of 45 SRs/MAs were included. After AMSTAR2 evaluation, only two (4.4%) of 45 SRs/MAs were moderate, three (6.7%) were rated as low quality, and the remainder 40 (88.9%) were rated as critically low quality. Among the 16 items of AMSTAR2, item 3 and item 10 had the poorest adherence. Item 4 received the most significant number of \"Partial Yes\" responses. Univariable analysis indicated that there were significant differences in methodological quality in SRs between different continents (P = 0.027) as well as between preregistered SRs and those that were not (P = 0.004). However, in multivariate analysis, there was no significant association between methodological quality and the following research characteristics: publication year, continent, whether reporting followed Preferred Reporting Items for Systematic Reviews (PRISMA), preregistration, funding support, randomized controlled trials (RCT) enrollment, whether SR was published in the Cochrane Database of Systematic Reviews (CDSR), and whether with meta-analysis. Additionally, subgroup analysis based on interventional SRs/MAs showed that continent was independently associated with the methodological quality of SRs/MAs of CP/CPPS via univariable and multivariate analysis.
    Our study demonstrates that the methodological quality of SRs/MAs of CP/CPPS was generally poor. SRs/MAs of CP/CPPS should adopt the AMSTAR2 to enhance their methodological quality.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:电子尼古丁输送系统(ENDS),通常被称为电子烟,已经在临床研究中检查了它们对戒烟的影响。在过去的两年里,已经发表了十几篇或更多有关ENDS和戒烟的系统评价,对ENDS的使用提出了不同的结论和建议.
    目的:我们的综述旨在综合当前系统评价的结果,以调查使用ENDS戒烟率和戒烟率。此外,我们将与其他已建立的戒烟治疗方法相比,检查ENDS的戒烟率。
    方法:搜索将检索系统综述,其中包括使用ENDS戒烟的临床试验和实验研究。我们还将包括非随机队列研究,追踪ENDS的使用和随后的戒烟。数据库搜索将在Embase进行,Scopus,PubMed,和7个额外的登记册。次要搜索将包括参考检查,引用追逐,并与主题专家进行磋商。两名审稿人将执行标题和摘要排除,然后是完整的论文收录过程。数据提取将由1名审阅者进行,并由第二名审阅者进行完整检查。每个系统审查将由2名审查人员使用AMSTAR2(评估系统审查的测量工具,版本2),并使用循证医学中心的“偏见目录”中的类别报告偏见。将确定方案与已发布的审查之间未报告的差异。
    结果:伞式审查于2023年3月1日开始。在出版时,正在进行研究选择,数据提取和偏倚评估表的试点测试正在进行中。该审查预计将于2023年12月31日完成,随后将审查提交期刊出版。二阶荟萃分析将计算ENDS的戒烟率的范围和平均值。对效果方向的投票计数,根据戒烟率,与其他戒烟治疗(包括不治疗)相比,将用于呈现ENDS戒烟的相对有效性。引文矩阵将列出主要研究以及所有系统评价中的偏见评级。将使用校正的覆盖面积分析来计算系统评价之间的重叠研究的影响。敏感性分析将检查停止治疗的强度对戒烟率的影响。根据数据的可用性,亚组分析将根据参与者的性别进行,年龄,先前的戒烟尝试,尼古丁依赖。将使用证据分层技术评估证据综合的强弱。报告偏差将与偏差指标表一起显示。将评估出版偏见。
    结论:使用ENDS戒烟是一个非常有争议的话题。通过对现有数据的详尽综合,我们将介绍ENDS获得的戒烟率,以及它们如何与其他既定戒烟治疗获得的戒烟率进行比较。系统评价的关键质量和偏见评估将表明最可靠的来源,以告知治疗考虑和政策制定。
    背景:PROSPEROCRD42023406165;https://tinyurl.com/4ekzpbrj.
    PRR1-10.2196/47711。
    BACKGROUND: Electronic nicotine delivery systems (ENDS), commonly called e-cigarettes, have been examined in clinical studies for their effects on tobacco smoking cessation. In the past 2 years, a dozen or more systematic reviews on ENDS and cigarette smoking cessation have been published that present differing conclusions and recommendations on the use of ENDS.
    OBJECTIVE: Our umbrella review aims to synthesize the findings from current systematic reviews to investigate the quit rates and the percentage of participants abstinent from cigarette smoking using ENDS. Additionally, we will examine the quit rates with ENDS in comparison to other established cessation treatments.
    METHODS: The search will retrieve systematic reviews that include both clinical trials and experimental studies on the use of ENDS for smoking cessation. We will also include nonrandomized cohort studies that track ENDS use and the subsequent abstinence from smoking. Databases searches will be conducted in Embase, Scopus, PubMed, and 7 additional registries. Secondary searches will include reference checking, citation chasing, and consultations with topic experts. Two reviewers will perform a title and abstract exclusion followed by a full-paper inclusion process. Data extraction will be conducted by 1 reviewer and completely checked by a second reviewer. Each systematic review will be assessed by 2 reviewers for methodological quality using AMSTAR2 (A Measurement Tool to Assess Systematic Reviews, version 2) and for reporting bias using categories from the Centre for Evidence-Based Medicine\'s Catalogue of Bias. Unreported discrepancies between the protocol and the published review will be identified.
    RESULTS: The umbrella review started on March 1, 2023. At the time of publication, the study selection was being conducted and the pilot testing of the data extraction and bias assessment forms were in progress. The review is expected to be completed by December 31, 2023, followed by the submission of the review for journal publication. A second-order meta-analysis will calculate the range and average of quit rates for ENDS. A vote counting of the direction of effect, based on quit rates, will be used to present the relative effectiveness of ENDS for smoking cessation compared to other cessation treatments (including no treatment). A citation matrix will list primary studies with their bias ratings from all the systematic reviews. The effect of overlapping studies between the systematic reviews will be calculated using the corrected coverage area analysis. A sensitivity analysis will examine the impact of the intensity of cessation treatment on quit rates. Depending on the availability of data, subgroup analyses will be conducted based on participants\' gender, age, prior quit attempts, and nicotine dependence. The strength or weakness of the evidence synthesis will be assessed using a stratification of evidence technique. Reporting bias will be presented with a tabulation of bias indicators. Publication bias will be assessed.
    CONCLUSIONS: The use of ENDS for smoking cessation is a highly controversial subject. Through an exhaustive synthesis of the available data, we will present the quit rates of cigarette smoking cessation obtained with ENDS and how they compare to quit rates obtained from other established cessation treatments. The critical quality and bias assessment of the systematic reviews will indicate the most reliable sources to inform treatment considerations and policy development.
    BACKGROUND: PROSPERO CRD42023406165; https://tinyurl.com/4ekzpbrj.
    UNASSIGNED: PRR1-10.2196/47711.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    未经评估:已经发表了许多系统评价,比较了全膝关节置换术(TKA)中接受后稳定型(PS)和交叉保留(CR)手术的患者的预后,但是有一些重叠和矛盾。本研究的目的是(1)对TKA中PS与CR的比较进行当前系统评价的概述,通过评估他们的方法论质量和偏见风险,(2)通过最佳证据提供建议。
    未经评估:对比较TKA中PS和CR的系统评价进行系统搜索,在2021年6月之前发布的是使用MEDLINE进行的,EMBASE,和Cochrane图书馆数据库。通过AMSTAR2工具和ROBIS工具评估纳入的系统评价的方法学质量和偏倚风险,分别。最佳证据的选择是根据Jadad决策算法进行的。
    UNASSIGNED:共有8篇系统综述符合纳入本研究的条件。Jadad决策算法建议应选择AMSTAR2得分最高的评论。根据ROBIS工具,有3篇评价偏倚风险低,5篇评价偏倚风险高.因此,Verra等人进行的一项系统评价。选择AMSTAR2评分最高且偏倚风险低的证据作为最佳证据.
    UASSIGNED:尽管目前的系统评价显示PS和CR在临床表现和功能结局方面存在一些统计学差异,目前的结果指标不能为进行PS或CR提供建议。选择假体的决定主要基于外科医生的偏好,指标和其他指标。
    UNASSIGNED: Numerous systematic reviews have been published comparing the outcomes of patients undergoing posterior stabilized (PS) versus cruciate-retaining (CR) procedures in total knee arthroplasty (TKA), but with some overlaps and contradictions. The objectives of this study were (1) to perform an overview of current systematic reviews comparing PS versus CR in TKA, by evaluating their methodological quality and risk of bias, and (2) to provide recommendations through the best evidence.
    UNASSIGNED: A systematic search of systematic reviews comparing PS and CR in TKA, published until June 2021 was conducted using the MEDLINE, EMBASE, and Cochrane Library databases. Included systematic reviews were assessed for methodological quality and risk of bias by the AMSTAR2 instrument and ROBIS tool, respectively. The choice of best evidence was conducted according to the Jadad decision algorithm.
    UNASSIGNED: A total of eight systematic reviews were eligible for inclusion in this study. The Jadad decision algorithm suggested that reviews with the highest AMSTAR2 scores should be selected. According to the ROBIS tool, there were three reviews with a low risk of bias and five with a high risk of bias. Consequently, one systematic review conducted by Verra et al. with the highest AMSTAR2 score and low risk of bias was selected as the best evidence.
    UNASSIGNED: Although current systematic reviews demonstrated some statistical differences in clinical presentation and functional outcomes between PS and CR, the current outcome indicators cannot be taken to provide recommendations for undergoing PS or CR. The decision for prosthesis selection could be made mostly based on the surgeon\'s preference, indications and other indicators.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    系统评价和荟萃分析汇集了来自个别研究的数据,以产生更高水平的证据供指南评估。这些评论最终指导临床医生和利益相关者做出与健康相关的决策。然而,证据综合的信息量和质量本质上取决于已纳入元研究项目的质量。此外,除了纳入的个别研究的质量之外,只有一个方法正确的过程,关于系统评价和荟萃分析本身,可以产生可靠和有效的证据合成。因此,元研究项目的质量也会影响证据综合的可靠性。在本概述中,作者提供了一些最常用的工具的优缺点和主要特征的综合,以评估个别研究的质量,系统评价,和荟萃分析。具体来说,在这项工作中考虑的工具是纽卡斯尔-渥太华量表(NOS)和加强流行病学观察研究报告(STROBE)的观察研究,综合报告试验标准(CONSORT),Jadad量表,用于随机对照试验的Cochrane偏倚风险工具2(RoB2),系统评价和荟萃分析(PRISMA)和多重系统评价2(AMSTAR2)的首选报告项目,和AMSTAR-PLUS进行荟萃分析。已经知道什么?:证据合成的信息量和质量本质上取决于已汇集到元研究项目中的质量。除了纳入的个别研究的质量之外,只有一个方法正确的过程,关于系统评价和荟萃分析本身,可以产生可靠和有效的证据合成。什么是新的?:在本概述中,作者提供了一些最常用的工具的优缺点和主要特征的综合,以评估个别研究的质量,系统评价,和荟萃分析。潜在影响:本概述作为起点和简要指南,用于识别和理解评估元研究中包含的研究质量的主要和最常用的工具。这里的作者分享了他们发表几篇涵盖医学科学不同领域的元研究相关文章的经验。
    Systematic reviews and meta-analyses pool data from individual studies to generate a higher level of evidence to be evaluated by guidelines. These reviews ultimately guide clinicians and stakeholders in health-related decisions. However, the informativeness and quality of evidence synthesis inherently depend on the quality of what has been pooled into meta-research projects. Moreover, beyond the quality of included individual studies, only a methodologically correct process, in relation to systematic reviews and meta-analyses themselves, can produce a reliable and valid evidence synthesis. Hence, quality of meta-research projects also affects evidence synthesis reliability. In this overview, the authors provide a synthesis of advantages and disadvantages and main characteristics of some of the most frequently used tools to assess quality of individual studies, systematic reviews, and meta-analyses. Specifically, the tools considered in this work are the Newcastle-Ottawa scale (NOS) and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) for observational studies, the Consolidated Standards of Reporting Trials (CONSORT), the Jadad scale, the Cochrane risk of bias tool 2 (RoB2) for randomized controlled trials, the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and the Assessment of Multiple Systematic Reviews 2 (AMSTAR2), and AMSTAR-PLUS for meta-analyses. WHAT IS ALREADY KNOWN?: The informativeness and quality of evidence synthesis inherently depend on the quality of what has been pooled into meta-research projects. Beyond the quality of included individual studies, only a methodologically correct process, in relation to systematic reviews and meta-analyses themselves, can produce a reliable and valid evidence synthesis. WHAT IS NEW?: In this overview, the authors provide a synthesis of advantages and disadvantages and main characteristics of some of the most frequently used tools to assess quality of individual studies, systematic reviews, and meta-analyses. POTENTIAL IMPACT: This overview serves as a starting point and a brief guide to identify and understand the main and most frequently used tools for assessing the quality of studies included in meta-research. The authors here share their experience in publishing several meta-research-related articles covering different areas of medical sciences.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    To assess the relative importance of A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR2) items.
    A best-worst scaling object case was conducted among a sample of experts in the field of systematic reviews (SRs) and meta-analyses (MAs). Respondents were asked in a series of 15 choice tasks to choose the most and the least important item from a set of four items from the master list, which included the 16 AMSTAR2 items. Hierarchical Bayes analysis was used to generate the relative importance score for each item.
    The most important items highlighted by our 242 experts to conduct overview of reviews and critically assess SRs/MAs were the appropriateness of statistical analyses and adequacy of the literature search, followed by items regarding the assessment of risk of bias, the research protocol, and the assessment of heterogeneity (relative importance score >6.5). Items related to funding sources and the assessment of study selection and data extraction in duplicate were rated as least important.
    Although all AMSTAR2 items can be considered as important, our results highlighted the importance of keeping the two items (the appropriateness of statistical analyses and the adequacy of the literature search) among the critical items proposed by AMSTAR2 to critically appraise SRs/MAs.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    简介:本文严格审查了癌症患者补充疗法的系统评价(SR)和荟萃分析(MA),以评估证据水平,并为今后的研究和实践提供建议。方法:从成立到2018年1月,搜索Cochrane图书馆和MEDLINE,以确定可用于癌症患者的补充疗法的SR和MA。最终选择的SR和MA通过应用评估系统评价2(AMSTAR2)工具对其质量进行方法学评估。数据提取和质量风险评估由2名独立评审员进行。结果:共有104项研究纳入分析。SR和MA中包含的大多数个体临床试验在中国(48%)和美国(26.9%)进行。乳腺癌是研究最多的癌症类型(25%),针灸是研究最多的干预措施(21%)。癌症的副作用,如疼痛,抑郁症,和疲劳得到有效的管理与补充疗法。方法上有问题的项目包括未列出排除的研究以及缺乏方案或方案注册。结论:随着人们对研究的兴趣日益浓厚,补充疗法似乎有利于减少副作用和提高癌症患者的生活质量。补充疗法通常被研究用于所有癌症,针灸是研究最多的,无论癌症类型。由于AMSTAR2是一个比以前更严格的评估工具,未来的研究需要谨慎考虑方法学偏差的风险,并讨论适当的总体质量评估工具.
    Introduction: This article critically examines the systematic reviews (SR) and meta-analysis (MA) of complementary therapies for cancer patients to appraise the evidence level, and offers suggestions for future research and practice. Methods: The Cochrane Library and MEDLINE were searched from their inception to January 2018, to identify SR and MA of complementary therapies available for cancer patients. Final selected SR and MA were methodologically evaluated for their quality by applying the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR2) instrument. Data extraction and risk of quality assessments were performed by 2 independent reviewers. Results: A total of 104 studies were included in the analysis. The majority of the individual clinical trials included in the SR and MA were performed in China (48%) and the United States (26.9%). Breast cancer was the most studied cancer type (25%), and acupuncture was the most studied intervention (21%). Side effects of cancer such as pain, depression, and fatigue were effectively managed with complementary therapies. The methodologically problematic items included not listing the excluded studies and lack of protocol or protocol registration. Conclusions: With increasing interest in research, complementary therapies appear to be beneficial in reducing side effects and raising the quality of life of cancer patients. Complementary therapies have generally been studied for all cancers, with acupuncture being the most researched, regardless of the cancer type. Since AMSTAR2 is a stricter assessment tool than before, future studies need to consider the risk of methodological bias with caution and discuss appropriate overall quality assessment tools.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

公众号